期刊文献+

尖锐湿疣患者血清及宫颈分泌物HPV6bE7抗体检测方法的建立及流行病学意义 被引量:2

Studies on the establishment of a method to detect HPV 6b E7-specific antibodies of serum and cervical secretion from patients with condyloma acuminatum and its epidemiological significance
原文传递
导出
摘要 目的建立尖锐湿疣(CA)患者血清和宫颈分泌物人乳头瘤病毒(HPV)6b型E7特异性抗体检测方法。方法利用PCR扩增HPV6bE7全长基因,构建重组原核表达质粒pET32a(+)/HPV6bE7,原核表达产物采用SDS—PAGE和Western blot进行鉴定。进一步经镍螯合亲和层析法(Ni—NTAAgarose)纯化后作为包被抗原,以间接ELISA方法分别对56例CA患者、81名健康对照者的血清和宫颈分泌物标本巾的特异性抗体进行检测,另取43例宫颈癌患者的血清标本作为对照;同时用PCR方法对56例CA组织标本进行HPV6bDNA的检测。结果从CA组织标本中扩增的HPV6bE7全长基因与标准序列(GenBank登录号:NC001355)同源性为99.5%。HPV6bE7融合蛋白在原核表达系统中得到了较高效的表达(40μg/ml)。经间接ELISA检测,CA组血清特异性IgG抗体水平明显高于宫颈癌组和健康对照组(P〈O.05),吸光度(A)均值分别为1.82±0.48、1.36±0.39和1.39±0.27。CA组宫颈分泌物特异性slgA抗体水平亦显著高于健康对照组(P〈0.05),A值分别为O.63±0.26和0.53±0.06。经PCR检测,CA患者组织HPV6bE7DNA阳性率为78.6%(44/56)。与PCR检测结果比较,HPV6bE7特异性IgG和sIgA抗体用于检测CA患者HPV6b感染的敏感性分别为68.2%(30/44)、54.6%(24/44),特异性均为100%(12/12)。结论CA患者血清和宫颈分泌物HPV6bE7特异性抗体,用于诊断HPV6b感染具有一定的敏感性和较高的特异性,可用于HPV6b感染的流行病学调查。 Objective To establish a method for detection of the human papillomavirus (HPV) 6b E7-speeific antibodies in serum and cervical secretion from patients with condyloma acuminatum (CA). Methods A full-length HPV 6b E7 gene was amplified by PCR from the CA tissue to construct the recombinant plasmid pET32a ( + )/HPV 6b E7. The expression of prokaryotic protein was analyzed by SDS-PAGE and Western blot, then purified with Ni-NTA Agarose affinity column and used as an diagnostic antigen for establishing indirect ELISA method, to detect specific serum IgG and specific cervical secretion sIgA from 56 CA patients, 81 healthy control. Sera from 43 cervical cancer was served as control. HPV 6b DNA from 56 CA patients was identified by PCR. Results Data showed that the nucleotide homology of cloned sequence was 99.5%, compared to the standard sequences of HPV 6b E7 gene (GenBank accession number: NC001355). A high level expression of E7 fusion protein was obtained in prokaryotic expression system (40 μg/ml). Based on HPV 6b E7 fusion protein being used as coating antigen, results from ELISA showed that the absorbance rates (A) of serum IgG from CA, cervix cancer and healthy control groups were 1.82 ± 0.48, 1.36±0.39 and 1.39±0.27, respectively. The level of IgG antibody in the serum of CA group was significantly higher than that in cervix cancer group and healthy control (P〈0.05). The A values of cervical secretion sIgA in CA and healthy control groups were 0.63 ± 0.26 and 0.53 ±0.06, respectively, while the level of sIgA antibody in the cervical secretion of CA group was also significantly higher than that in healthy controls (P〈0.05). The positive rate of HPV 6b E7 DNA in CA tissue was 78.6% (44/56) by PCR method. When compared the results measured by PCR, the HPV 6b E7-specific IgG and sIgA antibodies by ELISA used to detect the patients infected with HPV 6b infection, showed that the sensitivity rates were 68.2% (30/44) and 54.6% (24/44) respectively, and the specificity were all 100% (12/12). Conclusion Based on the serum and cervical secretion specific HPV 6b E7 antibodies from patients with CA to diagnose HPV 6b infection, results showed medium sensitivity and high specificity, and could further be used to investigate the epidemiological characteristics of HPV 6b infection.
出处 《中华流行病学杂志》 CAS CSCD 北大核心 2010年第2期199-203,共5页 Chinese Journal of Epidemiology
基金 基金项目:国家自然科学基金(30671882) 浙江省医药卫生重点科技基金(2005ZD011) 温州市科技计划项目(Y20060081)
关键词 尖锐湿疣 人乳头瘤病毒 血清 宫颈分泌物 6b E7抗体 Condylomata acuminata Human papillomavirus Serum Cervical secretion 6b E7-speeific antibodies
  • 相关文献

参考文献11

  • 1Favre M, Ramoz N, Orth G. Human papillomavirus: general features. Clin Dermatol, 1997,15(2) : 181-198.
  • 2Munger K, Basile JR, Duensing S, et al. Biologieal activities and molecular targels of the human papillomavints E7 oncoprotein. Oncogene, 2001,20 : 7888-7898.
  • 3郑丹,张德意,石朝辉,涂权梅,欧琴,李琼英,张丽芳.人乳头瘤病毒11型E7蛋白在原核细胞的表达及其诊断尖锐湿疣的价值[J].中华检验医学杂志,2007,30(3):276-279. 被引量:2
  • 4Clifford G, Franceschi S, Diaz M, et al. HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine, 2006,24 : 26-34.
  • 5Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Inter J Cancer, 2007, 121 (3) : 621-632.
  • 6Hicheri J, Jaber K, Dhaoui MR, et al. Giant condyloma(Buschke- Lowenstein tumor). A case report, Acta Dermatovene APA, 2006,15(4) : 181-183.
  • 7Stanley MA. Human papillomavirus vaccines. Rev Med Virol, 2006,16(3 ) : 139-149.
  • 8Zhang LF, Zhou J, Chen S, et al. HPV 6b virus like particles are potent immunogens without adjuvant in man. Vaccine, 2000, 18 (11): 1051-1058.
  • 9陈韶,周凯,夏克栋,陈柏坤,陈向敏,张丽芳.HPV6b VLPs检测尖锐湿疣病人血清和宫颈分泌物抗体的意义[J].温州医学院学报,2003,33(2):79-81. 被引量:2
  • 10Kedzia W, Olejnik A, Schmidt M, et al. The level of antibody against E6 HPV 16 on coprotein in blood sera of women with chronic HPV 16 infection and cervical cancer. Eur J Gynaeeol Oncol,2006,27( 1 ) : 65-68.

二级参考文献13

  • 1刘跃华,刘晓松,IanH.Frazer.人乳头瘤病毒6b型病毒样颗粒免疫活性的研究[J].中华医学杂志,2002,82(9):587-589. 被引量:7
  • 2Munger K, Basile JR, Duensing S, et al. Biologieal activities and molecular targels of the human papiUomavints E7 oncoprotein.Oncogene, 2001,20:7888-7898.
  • 3Heim k, Christensen ND, Hoepfl R, et al. Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles indifferent gynecologic patient groups. J Infect Dise,1995,172 : 395-402.
  • 4Carter JJ, Wipf GC, Hagensee ME, et al. Use of human papiUomavirus type 6 capsids to detect antibodies in people with genital warts. J Infect Dise, 1995,172:11-18.
  • 5Marais DJ, Rose RC, Lane C, et al. Serorespanses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia. J Med Virol, 2000,60:403-430.
  • 6Stanley MA. Human papillomavirus vaccines. Rev Med Virol,2006,16 : 139-149.
  • 7Nardelli-Haefliger D, Lurati F, Wirthner D, et al. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine.Vaccine, 2005,23:3634-3636.
  • 8Zhang LF, Zhou J, Chen S, et al. HPV6b L1 virus like particles are potent immunogens without adjuvant in man. Vaccine, 2000,18 : 1051-1058.
  • 9Ravaggi A, Romani C, Pasinetti B, et al. Correlation between serological immune response analyzedby a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. Arch Viro1,2006,151 : 1899-1916.
  • 10张丽芳,郑飞云,林巧爱,朱雪琼,陈素华,包其郁.性罪错妇女生殖道人乳头瘤病毒检测及型别分析[J].中华皮肤科杂志,1998,31(3):183-184. 被引量:16

共引文献1

同被引文献16

引证文献2

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部